摘要
目的探讨复方丹参滴丸联合拉米夫定治疗活动性肝硬化的临床疗效。方法将82例活动性肝硬化患者随机分为两组,治疗组42例,口服复方丹参滴丸加拉米夫定治疗。对照组40例,5%葡萄糖注射液250ml加甘利欣注射液30ml静脉点滴,1个月后改用甘利欣胶囊口服治疗。观察治疗前、后两组患者肝功能及治疗前和治疗开始后1、3、6、12个月的HBVDNA变化,比较HBVDNA阴转率。结果治疗后两组患者丙氨酸氨基转移酶、天冬门氨酸氮基转移酶和总胆红素水平间差别均有显著性意义(P<0.05),HBV-DNA的阴转率间差别亦有显著性意义(P<0.05)。结论复方丹参滴丸加拉米夫定对活动性肝硬化有明显的疗效,值得临床推广应用。
Objective To investigate the clinical effect of Compound Danshen pill and Lamivudine on the active hepatic cirrhosis, Methods Totally 42 patients with active hepatic cirrhosis were randomly divided into two groups. The patients in the trial group received Compound Danshen pill and Lamivudine; the patients in the control group received Diammonium Glycyrrhizinate. The liver function before and after treatment of the patients in the two groups, and the change of HBV - DNA at 1, 3, 6, 12 months after treatment were detected. Results The values of ALT, AST and total bilirubin in trial group were decreased comparing with the control groups, with a significant differences （ P 〈 0.05）. There was also a significant difference in negative rate of HBV - DNA between trial group and control group （ P 〈 0.05）. Conclusion Compound Danshen pill and Lamivudine showed an obvious effect in the treatment of active hepatic cirrhosis.
出处
《中国全科医学》
CAS
CSCD
2007年第1期64-65,共2页
Chinese General Practice
关键词
复方丹参滴丸
拉米夫定
肝硬化
药物疗法
Fufang danshen drop pill
Lamivudine
Liver cirrhosis
Drug therapy
